Dr. Barer has more than 30 years of experience with publicly traded biotechnology companies. At Celgene Corporation [CELG], he spent 18 years leading Celgene as president, COO and CEO, culminating with his tenure as Celgene’s executive chairman and chairman before retiring in June 2011. Under his helm, Celgene became the third largest independent biotechnology company in the world and a member of the S&P 500 with a current market capitalization exceeding $35 billion. Dr. Barer serves on the Board of several companies including: Amicus Therapeutics, Inc. [FOLD] and Aegerion Pharmaceuticals, Inc. [AEGR], and is Chairman of the Board of Cerecor, Inc, ContraFect Corp., InspireMD, Inc. and Medgenics, Inc. [MDGN].

Over the past three decades, Mr. Blech has become one of the most successful private financiers in the biotechnology industry. He has been instrumental in establishing some of the world’s leading biotechnology companies including Celgene Corporation, Genetic Systems Corporation, ICOS Corporation, Nova Pharmaceutical Corporation and PathoGenesis Corporation. These companies are responsible for major advances in oncology, infectious disease and cystic fibrosis. Current roles include: Founder, Vice Chairman, Cerecor, Inc., a private company developing new treatments for central nervous system disorders; Director, ContraFect Corporation, a private company developing therapies for infectious diseases; Vice Chairman, Premier Alliance Group, an energy and financial regulation consulting company; Director, Medgenics, Inc.; and Vice Chairman, BillMyParents, Inc., an innovator in e-commerce for the youth market.

“We are honored to welcome Mr. Blech to our Board of Directors and are extremely pleased that Dr. Barer has agreed to take on additional responsibilities,” said Brian Leuthner, co-founder and CEO of Edge Therapeutics. “We are confident that with their guidance Edge can build a commercial biopharmaceutical company well-positioned to develop valuable and potentially life-saving therapies that address complications after ruptured brain aneurysms, subdural hematomas, and other types of brain hemorrhage.”

“Edge is seeking to build novel products using a site specific, sustained release microparticle technology platform,” said Isaac Blech. “I am delighted to help Edge Therapeutics build the capabilities and organizational structure needed to carry its products through clinical trials, regulatory approval and ultimately to the patients who can benefit from these therapies.”

About Edge Therapeutics

Edge Therapeutics is a clinical-stage, hospital-focused biopharmaceutical company that uses its novel site-specific and sustained-release microparticle technology platform to deliver drugs to the brain to prevent complications occurring after subarachnoid hemorrhage, subdural hematoma and intracerebral hemorrhage, all of which currently have minimally effective or no effective therapies. Edge works with some of the world’s foremost scientists and critical care physicians from leading academic research centers to develop proprietary formulations of known active drugs for direct therapeutic delivery to the site of injury in the brain.

The Company’s patent-pending bio-absorbable microparticle formulations release drugs locally and consistently at therapeutic concentrations in the brain, with the objective of maximizing therapeutic activity and avoiding treatment-limiting systemic side effects seen with current treatments. Currently, oral- or i.v.-administered therapies are employed but in suboptimal concentrations due to the generation of systemic side effects. Edge’s lead products, EG-1962 (nimodipine microparticles) and EG-1964 are being developed to prevent various delayed complications after brain hemorrhage. EG-1962 is a proprietary microparticle formulation of the generic calcium channel blocker nimodipine, while EG-1964 delivers a hemostatic agent. For more information on Edge Therapeutics, Inc., please visit: www.edgetherapeutics.com

For more information contact:

Edge Therapeutics, Inc.
Brian A. Leuthner
President & CEO
800-208-EDGE

“Dr. Langer’s experience and leadership in successfully guiding sustained-release drug development programs from the research stage through commercialization will bring an invaluable perspective to Edge,” said Brian A. Leuthner, President and CEO of Edge. “Edge stands to benefit greatly from his deep understanding and commitment to translating cutting-edge science into life-saving therapies as we work to fulfill our primary mission of saving lives.”

A world-renowned scientist and entrepreneur with vast experience in the healthcare, biotechnology and pharmaceutical industries, Dr. Langer is the David H. Koch Institute Professor at the Massachusetts Institute of Technology (MIT). He is the author of more than 1,100 journal articles and the most cited engineer in history. A pioneer in drug-delivery-related inventions, his patents have been licensed or sub-licensed to over 220 companies worldwide. Dr. Langer has been named by Time magazine and CNN as one of the 100 most important people in America, and he is also a recipient of the Charles Stark Draper Prize, which is equivalent to the Nobel Prize for engineers.

“Getting involved with Edge allows me to once again focus time and attention on delivering drugs to the brain, which has been an interest and passion of mine for decades,” said Dr. Langer. “This is an exciting time at Edge as they transition into a clinical-stage company while still seeking to expand their platform of potentially life-saving therapies for the treatment of acute and critical care conditions such as ruptured brain aneurysms, subarachnoid hemorrhage, subdural hematoma, intracerebral hemorrhage and brain cancers all of which are unsatisfactorily treated critical care conditions.”

“Dr. Langer is one of the most accomplished scientists ever in the field of drug delivery,” said R. Loch Macdonald, M.D., Ph.D., Edge co-founder and Chief Scientific Officer. “The opportunity to work with Bob to optimize and expand our pipeline of treatments for unmet critical care conditions is a great honor.”

About Edge Therapeutics

Edge Therapeutics is a clinical-stage, hospital-focused biopharmaceutical company that uses its novel      site-specific and sustained-release microparticle technology platform to deliver drugs to the brain to prevent complications of subarachnoid hemorrhage, subdural hematoma and intracerebral hemorrhage, all of which currently have no effective therapies. Edge works with some of the world’s foremost scientists and critical care physicians from leading academic research centers to develop proprietary formulations of known active drugs for direct therapeutic delivery to the site of injury in the brain.

The Company’s patent-protected bio-absorbable microparticle formulations release drugs locally and consistently at therapeutic concentrations in the brain, with the objective of maximizing therapeutic activity and avoiding treatment-limiting systemic side effects seen with current treatments. Currently, oral- or    i.v.-administered therapies are employed but in suboptimal concentrations due to the generation of systemic side effects. Edge’s lead products, EG-1962 (nimodipine microparticles) and EG-1964 are being developed to prevent various delayed complications after brain hemorrhage.  EG-1962 is a proprietary microparticle formulation of the generic calcium channel blocker nimodipine, while EG-1964 delivers a hemostatic agent. For more information on Edge Therapeutics, Inc., please visit: www.edgetherapeutics.com

For more information contact:

Edge Therapeutics, Inc.
Brian A. Leuthner
President & CEO
800-208-EDGE

Trenton, NJ – Capping a month long tour to better inform economic development policy by getting direct insight from businesses in New Jersey’s life sciences industry, Lt. Governor Kim Guadagno today visited the Enterprise Development Center (EDC) at the New Jersey Institute of Technology (NJIT). The visit and tour to the EDC, home to nearly 86 high-tech and life science companies, was the Lt. Governor’s final stop in her Business Life Sciences Tour across the Garden State that occurred throughout the month of June. The Lt. Governor visited twelve life sciences companies during the month.

The visit included meeting with the executives of four resident companies: Edge Therapeutics, Inc. a drug development company that is working to reduce the effects of traumatic brain injury; SimPhoTek, Inc., a global leader in the simulation of laser; Endomedix, Inc., a developer of medical devices that is working on a product to control surgical bleeding and Menssana Research, Inc., a developer of medical devices that has designed a portable breath collection apparatus that can collect breath samples virtually anywhere, for highly sensitive laboratory analysis.

“The Enterprise Development Center plays a valuable role in helping start-up life sciences companies succeed. It provides a place where even the smallest companies can develop ideas and products that will have great benefits to human health world-wide,” said Lt. Governor Guadagno. “We’re confident that these small companies will grow and expand to employ thousands of New Jerseyans for years into the future.”

“Lt. Governor Guadagno’s focus on the life sciences in June demonstrates the Christie Administration’s commitment to growing New Jersey’s premier industry,” said Dean J. Paranicas, president and chief executive officer of the HealthCare Institute of New Jersey. “In visiting life sciences companies around the state, speaking out on behalf of the industry and playing a prominent role at the BIO International Convention to promote New Jersey, the Lt. Governor has been  an enthusiastic and committed ambassador and advocate for our life sciences industry.”

EDC companies have access to NJIT facilities and can partner with researchers to help grow their business. Located in the heart of Newark’s University Heights Science Park and the Newark Innovation Zone, the EDC has created over 799 jobs including student hires. The company’s success has helped to graduate over 90 successful businesses by finding the right work spaces suitable for them, attracting investment capital, and helping them build marketing strategies and hard working staff members. According to the National Business Incubation Association (NBIA), 84 percent of its members report that incubator graduates stay in their communities.

“Through the New Jersey Partnership For Action, the Christie Administration is providing business advocacy services and meaningful regulatory and tax policy reforms so that companies – whether a start-up or a multi-national – have the tools available to them in New Jersey to take innovation from the classroom to the laboratory and on to the marketplace,” continued Lt. Governor Guadagno. “With the support of our Administration and business incubators such as the EDC, even the smallest life science companies have the ability to accomplish big things.”

Led by Lt. Governor Guadagno, the Partnership For Action (PFA) supports the vital role business plays in advancing the state’s economy and creating jobs. The PFA is a three-pronged public-private approach to economic development and the starting point for all initiatives, policies, and efforts to grow New Jersey’s economy and create quality, sustainable jobs in our communities. The three elements of the PFA include the Business Action Center reporting directly to the Lt. Governor and providing the business community with a single point of contact, applying a proactive, customer-service approach to businesses’ interactions with State government; the New Jersey Economic Development Authority, serving as the state’s “bank for business;” and Choose New Jersey, an independently funded and operated 501(c)(3) not-for-profit corporation created to encourage and nurture economic growth throughout New Jersey.

Businesses considering a move or in need of assistance are encouraged to call New Jersey’s Business Action Center at (866) 534-7789 or visit the State’s Business Portal at www.newjerseybusiness.gov.

Press Contact:
Ernest Landante
609-777-2535

New Providence, NJ and Toronto, Canada – June 08, 2012 – Edge Therapeutics, Inc. and St. Michael’s Hospital, an affiliate of the University of Toronto, announced today that the Government of Canada has awarded up to CA$700,000 to match equal expenditures by Edge for advancing a Phase 2 clinical trial of Edge’s lead compound. This funding from the Federal Economic Development Agency for Southern Ontario (FedDev), administered through The Ontario Brain Institute (OBI), is part of an CA$11-million initiative to accelerate the commercialization of 14 innovative neurotechnology projects.

Edge, a clinical-stage, hospital-focused biopharmaceutical company, and St. Michael’s Hospital, ranked third in academic impact among approximately 100 neurosurgery departments in North America*, also announced today that they will collaborate on Phase 2 clinical testing of Edge’s novel, site-specific and sustained-release nimodipine microparticle formulation (NimoVent™) that is designed to prevent delayed cerebral ischemia (DCI), a leading cause of permanent brain damage or death after brain injury.

“Today, patients with brain hemorrhage face life-threatening delayed complications, and only marginally effective treatment options are available,” said R. Loch Macdonald, MD, PhD, Head of the Division of Neurosurgery, Keenan Endowed Chair in Surgery at St. Michael’s Hospital and Chief Scientific Officer of Edge Therapeutics. “This research collaboration will allow us to further advance a much needed therapy.”

“This novel partnership spanning academia, industry, and government will accelerate development of promising technologies and bring them to the market more quickly,” said Dr. Arthur S. Slutsky, Vice-President of Research at St. Michael’s Hospital.

“By collaborating with St. Michael’s, Edge gains access to world-class experts in neurosurgery, established clinical research capabilities, and significant government funding. It also helps us fulfill our primary mission of saving lives,” said Brian Leuthner, President and CEO of Edge Therapeutics.

About Edge Therapeutics

Edge Therapeutics is a clinical-stage, hospital-focused biopharmaceutical company that uses its novel site-specific and sustained-release microparticle technology platform to deliver drugs to the brain for the treatment of acute, and fatal or debilitating neurological conditions that currently have no effective therapies. Edge works with some of the world’s foremost scientists from leading academic research centers to develop proprietary formulations of known active drugs for direct therapeutic delivery to the site of injury in the brain.

The Company’s patent-protected bio-absorbable microparticle formulations release drugs locally and consistently at therapeutic concentrations in the brain, with the objective of maximizing therapeutic activity and avoiding treatment-limiting systemic side effects seen with current treatments. Currently, oral- or i.v.-administered therapies are employed but in suboptimal concentrations due to the generation of systemic side effects. This technology platform is the basis of Edge’s pipeline of drugs in therapeutic areas such as complications from spontaneous brain hemorrhage, traumatic brain injury and brain surgery. Edge’s lead products, NimoVent™, EG-1964, and NimoGel™ are being developed to prevent various delayed complications after brain hemorrhage. NimoVent and NimoGel are different proprietary formulations of the generic calcium channel blocker nimodipine, while EG-1964 delivers a hemostatic agent. For more information on Edge Therapeutics, Inc., please visit: www.edgetherapeutics.com

About St. Michael’s Hospital

St. Michael’s Hospital provides compassionate care to all who enter its doors. The hospital also provides outstanding medical education to future health care professionals in more than 23 academic disciplines. Critical care and trauma, heart disease, neurosurgery, diabetes, cancer care, and care of the homeless are among the hospital’s recognized areas of expertise. Through the Keenan Research Centre and the Li Ka Shing International Healthcare Education Center, which make up the Li Ka Shing Knowledge Institute, research and education at St. Michael’s Hospital are recognized and make an impact around the world. Founded in 1892, the hospital is fully affiliated with the University of Toronto. For additional information about St. Michael’s Hospital, please visit: www.stmichaelshospital.com

About FedDev Ontario

With a five-year mandate, the Federal Economic Development Agency for Southern Ontario (FedDev Ontario) was launched in August 2009 to help respond to Ontario’s economic challenges. Through its funding initiatives, FedDev Ontario (www.feddevontario.gc.ca) is driving economic and community development, innovation, and economic diversification, while contributing to the success of communities, businesses, educational institutions and not-for-profit organizations. All of these activities contribute to FedDev Ontario’s vision: a prosperous and globally competitive Ontario.

About the Ontario Brain Institute (OBI)

Launched in November 2010, the OBI has been established to become an internationally recognized centre of excellence in brain research, translation and innovation. It will achieve its vision by initiating, funding, promoting and stimulating brain research, education and training. The research outcomes will be translated into clinical applications and commercialization opportunities related to the prevention, early diagnosis, treatment and management of brain diseases and disorders. The Institute is an independent, not-for-profit corporation funded by the Government of Ontario. The OBI will serve as a nexus for collaborative efforts, with a program focused on bringing together Ontario’s leading scientists and clinicians drawn from Ontario’s universities, colleges, and hospitals. For additional information about the Ontario Brain Institute, please visit: www.braininstitute.ca

For more information contact:

Edge Therapeutics, Inc.
Brian A. Leuthner
President & CEO
800-208-EDGE

St. Michael’s Hospital
Leslie Shepherd
Manager, Media Strategy
416-864-6094

Ontario Brain Institute
Lynn Butler
Manager, Government Relations & Strategic Communications
647-847-3136

________________________________

*J Neurosurg. 2010 Sep;113(3):447-57. Academic impact and rankings of American and Canadian neurosurgical departments as assessed using the h index

MATTAWAN, MI and NEW PROVIDENCE, NJ–(Marketwire – April 03, 2012) – MPI Research, the largest single-site preclinical contract research organization worldwide, and Edge Therapeutics, Inc., a hospital-focused biopharmaceutical company, announced today that they will collaborate on preclinical and clinical testing of Edge’s lead product candidates, NimoGel™, NimoVent™ and EG-1964. The companies will combine their skills and expertise with the goal of initiating clinical trials of Edge’s portfolio of therapies that use novel implantable technology to deliver proven drugs directly to the site of brain injury.

Paul Oskar, MBA, Vice President and General Manager of Drug Safety and Preclinical Sciences at MPI Research, notes, “We are impressed by Edge’s world-class science in brain hemorrhage and drug delivery. Together, MPI Research and Edge have the expertise and capabilities needed to accelerate the preclinical and clinical programs for Edge’s promising and potentially life-saving hospital-based therapies.”

The collaboration creates a preferred partnership relationship in which MPI Research will act as Edge’s primary service provider for pharmacologic, analytical, and safety in preclinical testing, and will also provide analytical services for clinical testing. This collaboration will allow Edge to gain multiple cost efficiencies while still retaining asset ownership and ownership of its strategic decision-making.

“Partnering with MPI Research allows Edge to access additional expertise and capabilities on a larger scale, helping to advance our lead hospital products into clinical trials,” said R. Loch Macdonald, MD, PhD, Edge Chief Scientific Officer and neurosurgeon. “We look forward to a strong collaboration focused on the shared goal of saving the lives of brain-injured patients.”

About MPI Research

MPI Research, with global headquarters in Mattawan, Michigan, is one of the world’s leading providers of comprehensive preclinical and early clinical research for pharmaceutical and biotechnology companies. In addition to a wide array of drug safety evaluation services, MPI Research Discovery Sciences Center offers experimental therapeutics (in vivo, molecular and cell-based assays), experimental surgery, molecular imaging, drug metabolism, pharmacokinetics, and immunology. The company also offers medical device evaluation, bioanalytical and analytical testing, and additional related services. Learn more about the company’s commitment to be the best at www.mpiresearch.com.

About Edge Therapeutics

Edge Therapeutics uses a novel, site-specific and sustained release-microparticle technology platform to deliver drugs to the brain and treat acute, and fatal or debilitating neurological conditions that currently have no effective therapies. Edge works with some of the world’s foremost scientists from leading academic research centers to develop proprietary and novel formulations of known active drugs for direct therapeutic delivery to the site of injury in the brain.

The company’s proprietary bio-absorbable microparticle formulations release drugs locally and consistently at therapeutic concentrations in the brain, which maximizes therapeutic activity while avoiding treatment-limiting systemic side effects seen with oral and intravenous delivery. This technology platform is the basis of Edge’s pipeline of drugs in therapeutic areas such as complications from spontaneous brain hemorrhage, traumatic brain injury and brain surgery. The lead products, NimoGel™ and NimoVent™, are microparticle formulations of the calcium channel blocker nimodipine. These drugs are being developed to prevent delayed complications after subarachnoid hemorrhage, (where today oral- or i.v.-administered nimodipine is employed but in suboptimal concentrations due to the generation of systemic side effects). Phase 2 studies for both NimoGel and NimoVent are planned for 2012 and early 2013. For more information on Edge Therapeutics, Inc., please visit www.edgetherapeutics.com

For more information contact:

MPI Research
Joan Manners
Senior Director of Marketing
joan.manners@mpiresearch.com

Edge Therapeutics, Inc.
Brian A. Leuthner
President & CEO
800-208-EDGE

NEW PROVIDENCE, NJ–(Marketwire – December 02, 2011) – Edge Therapeutics, Inc. announced today that the New Jersey Small Business Development Centers (NJSBDC) has named Edge a recipient of its 2011 Success Awards. The award recognizes companies and legislators for their commitment to the growth of small businesses representing a diverse array of industries including biotechnology, financial services, educational services, media and entertainment, food services and high-tech.

“Edge is a great example of what’s possible when talented and capable entrepreneurs apply their skills to a unique and innovative idea,” said Jerry Creighton, Sr., Executive Director of the NJIT-EDC and President of New Jersey Business Incubator Network. “The outcome is an emerging growth company! Everyone wins when you advance new scientific research.”

Edge Therapeutics is a hospital-focused biopharmaceutical company developing novel implantable technology for direct delivery of proven drugs to the site of brain injury. Edge began in 2009 as a New Jersey Institute of Technology Enterprise Development Center (NJIT-EDC) incubator company and has recently moved into its new commercial headquarters in New Providence, NJ.

“We are honored to be the recipient of a 2011 NJSBDC Success Award. It is a tremendous validation of the rapid progress we are making in developing life-saving therapies for civilians and soldiers that suffer brain hemorrhages,” said Brian Leuthner, President and Chief Executive Officer of Edge. “The New Jersey Small Business Development Centers along with the NJIT-EDC have been a vital resource for Edge as we grow.”

“Under the leadership of Brian Leuthner, Edge has grown rapidly with the support of non-dilutive partner funds and by securing equity financing,” noted Randy Harmon, New Jersey Small Business Development Centers Lead Technology Commercialization Consultant.

About Edge Therapeutics
Edge Therapeutics uses a novel, site-specific and sustained release-microparticle technology platform to deliver drugs to the brain and treat acute, and fatal or debilitating neurological conditions that currently have no effective therapies. Edge works with some of the world’s foremost scientists from leading academic research centers to develop proprietary and novel formulations of known active drugs for direct therapeutic delivery to the site of injury in the brain.

The company’s patent-protected, bioabsorbable microparticle formulations release drugs locally and consistently at therapeutic concentrations in the brain, which maximizes therapeutic activity while avoiding treatment-limiting systemic side effects seen with oral and intravenous delivery. This technology platform is the basis of Edge’s pipeline of drugs in therapeutic areas such as complications from spontaneous brain hemorrhage, traumatic brain injury and brain surgery. The lead products, NimoGel™ and NimoVent™, are microparticle formulations of the calcium channel blocker nimodipine. These drugs are being developed to prevent delayed complications after subarachnoid hemorrhage (where today oral- or i.v.-administered nimodipine is employed but in suboptimal concentrations due to the generation of systemic side effects). Phase 2 studies for both NimoGel and NimoVent are planned for 2012.

For more information on Edge Therapeutics, Inc., please visit www.edgetherapeutics.com.

Contact:
Edge Therapeutics, Inc.
Brian A. Leuthner
President & CEO
800-208-EDGE